We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Partnership to Promote Future Development of Multiplex Biomarker Testing

By LabMedica International staff writers
Posted on 06 Aug 2012
A partnership has been formed that combines the marketing prowess of a multinational manufacturer and distributor of life science research and clinical diagnostic products with the expertise of a leading multiplex biomarker testing company. More...


Under the terms of the agreement, Myriad RBM, Inc. (Austin, TX, USA) grants exclusive distribution rights, for research purposes, to Bio-Rad Laboratories, Inc. (Hercules, CA, USA). These rights apply to the large catalog of quantitative multiplexed immunoassays currently available to run on Bio-Rad's Bio-Plex 200, Bio-Plex 3D, and Bio-Plex MAGPIX instruments.

The assay kits acquired from Myriad RBM will expand the potential of Bio-Rad's instruments in the field of very low volume multiplex testing for research in toxicology, oncology, immunology, and cardiovascular and other diseases.

"Together we are able to provide hundreds of new biomarkers for both human and non-human panels to our Bio-Plex multiplex immunoassay system menu," said Brad Crutchfield, vice president and group manager of the life science group at Bio-Rad. "Moving forward, Myriad RBM and Bio-Rad will collaborate to design new products to meet the evolving requirements of our customers."

"This agreement combines Myriad RBM's industry-leading menu of multiplexed immunoassays with Bio-Rad’s unrivaled global commercial distribution capabilities," said Craig Benson, president of Myriad RBM. "Our partnership with Bio-Rad will help researchers and clinicians on the front lines of medicine to develop biomarker profiles that may predict, detect, or monitor disease progression in an effort to optimize treatment and improve patient care."

Related Links:
Myriad RBM, Inc.
Bio-Rad Laboratories, Inc.



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Automatic CLIA Analyzer
Shine i6000
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Xpert Hemorrhagic Fever Panel test runs on Cepheid’s GeneXpert Dx systems (Photo courtesy of Cepheid)

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.